少妇人妻无码专区毛片_蝌蚪视频窝在线播放_欧美性色欧美A在线播放_尤物在线精品视频_欧美精品国产一区二区三区_在线观看成人无码中文AV天堂不卡

以色列Pluristem Therapeutics Inc
luristem Therapeutics, Inc.從事間質干細胞的生產技術的研究和開發，以及細胞療法的產品的商品化。 該公司正開發一個平臺，這樣設計是為了創建一個功能干細胞的生產系統，可以治療重癥血液，心血管疾病，自身免疫性和其它疾病。 它開發了PluriX Bioreactor系統，該系統的設計是一個系統的基質干細胞的文化和襯底上，創建一個人工生理環境下，間質干細胞可以生長和繁殖以外的人體無任何使用外源性生物制品或生物克隆。 該公司成立于2001年，前身是AI Software, Inc.，在2003年公司改名為Pluristem Life Systems, Inc.，后來在2007年11月又改名為Pluristem Therapeutics, Inc.，公司位于以色列的Haifa。

Pluristem Therapeutics Inc. (NASDAQ: PSTI; DAX: PJT) is a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products derived from human placenta, a non-controversial, non-embryonic, adult stem cell source. The (PLacental eXpanded) cell products are stored off-the-shelf, ready-to-use, and require no histocompatibility matching.

These placental adherent stromal cells (ASCs) are expanded in the Company's proprietary PluriXTM 3D bioreactor system, which provides a 3D microenvironment that enables large-scale growth of these cells without the need for supplemental growth factors or other exogenous materials. PLX cells are immune privileged, possess immunomodulatory properties, and are expanded in vitro without showing signs of phenotypic or karyotypic changes. Pluristem believes that the PLX cells?mechanism of action may be related to the secretion of cytokines and/or other potent immune modulators.

Pluristem's first product, PLX-PAD (for the treatment of Peripheral Artery Disease), received from the Food and Drug Administration (FDA) and the Paul Ehrlich Institute (PEI), the German competent authority in the European Union, clearance to begin a 揊irst-In-Human?placental-derived mesenchymal-like stromal cell clinical trial.

Pluristem has offices in the USA with research and manufacturing facilities in Israel.